Arvinas Price Target Cut to $13.00/Share From $18.00 by HC Wainwright & Co.

What happened

HC Wainwright & Co. cut its price target on Arvinas to $13.00 per share from $18.00, while keeping a Buy rating on the stock.

Confirmed

Global impact / market context

The lower target still sits above the prior target cut, but a cut signals the analyst expects less upside than before. A Buy rating means the firm still sees the shares as worth owning despite the reduced estimate.

Analyst inference

Arvinas is a drug developer, so its value depends on clinical trial results and regulatory decisions. A lower price target reflects revised expectations for those milestones, not a change in the company's immediate cash or revenue.

Analyst inference

What to watch

1. HC Wainwright kept its Buy rating on Arvinas even as it lowered the price target to $13.00 from $18.00 per share. Confirmed
2. Watch whether other analysts follow with their own price target changes, which would show whether the reduced outlook is shared or isolated. Proposed
3. Watch Arvinas trial updates and regulatory news, since those events drive the drug developer's value and can justify or undercut the new target. Analyst inference

Evidence

• Original source link unavailable